The Univeristy of Melbourne The Royal Melbourne Hopspital

A joint venture between The University of Melbourne and The Royal Melbourne Hospital

Dr Danielle Anderson

Dr Danielle Anderson received her PhD from Curtin University of Technology in 2007, majoring in virology. She was a post-doctoral scientist at Intitut Armand-Frappier, Canada. At Duke-NUS Medical School in Singapore, she served as the Scientific Director of the ABSL3 laboratory, providing expertise, and support for research with pathogens requiring high containment.

At the Doherty Institute, she is a Research Scientist at the Royal Melbourne Hospital's Victorian Infectious Diseases Reference Laboratory. Her research is directed toward determining and understanding viral pathogenesis, particularly the influence of cellular host factors on paramyxovirus replication. Dr Anderson focuses is on pathogen discovery and aims to identify and characterise novel and emerging viruses and develop diagnostic platforms for the identification clinically relevant emerging pathogens, such as coronaviruses.

  • Key Achievements
    • Dr Danielle Anderson studies viral pathogenesis in animal models. In addition to molecular and virological laboratory expertise, she has extensive experience in designing high throughput studies and has trained and worked at BSL3 facilities in Singapore (Duke-NUS Medical School), Germany (Paul-Ehrlich-Institut) and the USA (Duke University), and a BSL4 facility in China (Wuhan Institute of Virology). Dr Anderson was part of the team that discovered SADS-CoV and Mengla filovirus. Her laboratory in Singapore was the fourth worldwide to isolate SARS-CoV-2. CIA Anderson is a co-inventor of cPass, a surrogate neutralization assay commercialized by GenScript that allows the detection of SARS-CoV-2 antibodies without the need for BSL3 containment.

    Loading ORCID data…